高等学校化学学报 ›› 2025, Vol. 46 ›› Issue (3): 20240480.doi: 10.7503/cjcu20240480

• 有机化学 • 上一篇    下一篇

HA-zein@QT纳米药物递送系统的微流控精准构建及性能研究

陈明慧1, 刘谟浩1, 李勇1, 程航1, 耿鹏2, 邱昆成1, 邓改改1(), 曾建红1(), 黄文权1()   

  1. 1.三峡大学健康医学院
    2.材料与化工学院, 宜昌 443002
  • 收稿日期:2024-10-23 出版日期:2025-03-10 发布日期:2024-11-26
  • 通讯作者: 邓改改,曾建红,黄文权 E-mail:denggaigai@ctgu.edu.cn;59747528@qq.com;huangwenquan@ctgu.edu.cn
  • 作者简介:第一联系人:共同第一作者.
  • 基金资助:
    湖北省自然科学基金(2024AFB059);三峡大学高层次人才科研启动及平台建设经费(拔尖人才)(8220309)

Microfluidic Precise Construction and Performance Studies of HA-zein@QT Nanodrug Delivery System

CHEN Minghui1, LIU Mohao1, LI Yong1, CHENG Hang1, GENG Peng2, QIU Kuncheng1, DENG Gaigai1(), ZENG Jianhong1(), HUANG Wenquan1()   

  1. 1.College of Medicine and Health Science
    2.College of Materials and Chemical Engineering,China Three Gorges University,Yichang 443002,China
  • Received:2024-10-23 Online:2025-03-10 Published:2024-11-26
  • Contact: DENG Gaigai, ZENG Jianhong, HUANG Wenquan E-mail:denggaigai@ctgu.edu.cn;59747528@qq.com;huangwenquan@ctgu.edu.cn
  • Supported by:
    the Natural Science Foundation of Hubei Province, China(2024AFB059);the Funds for Scientific Research Start-up and Platform Construction of China Three Gorges University High-level Talents(Top-notch Talents)(8220309)

摘要:

玉米醇溶蛋白(Zein)在抗癌药物递送系统(DDS)中表现出巨大的潜力, 但传统zein基DDS存在功能单一、 粒径不均一、 重现性差和抗癌效果差等缺陷. 本文以槲皮素(化学药物)-TCPP(光敏剂)为模型药(QT), 基于微流控技术调控载体与模型药物的共组装, 精准构建了HA-zein@QT纳米药物递送系统, 达到协同增效抗肿瘤的目的. 采用透明质酸(HA)功能化α-zein, 以提高载体的生物相容性、 稳定性和细胞摄取能力. 采用计算机仿真筛选出混合效率为99.54%的高效混合芯片, 通过该芯片制备的HA-zein@QT平均粒径为(50.6±1.7) nm, PDI为0.196. 稳定性实验表明, HA-zein@QT与去离子水、 PBS缓冲溶液和1640培养基共孵育后, 表现出较高的稳定性. 活性氧和·OH检测结果表明, HA-zein@QT暴露于近红外光可促进1O2和·OH生成. 生物相容性实验表明, 所制备DDS与血红细胞孵育后的溶血率仅为3.75%, 且与非肿瘤细胞共孵育后细胞存活率均大于84.57%, 证明其具有较高的生物相容性. 通过肿瘤细胞毒性研究发现, A549, HCT116和HCT8细胞的存活率分别为28.2%, 20.2%和24.6%, 表明HA-zein@QT对肿瘤细胞具有较高的抑制能力. 本文通过微流控精准构建zein基DDS, 为抗肿瘤药物的递送提供了一种高效、 低毒的新策略.

关键词: 玉米醇溶蛋白, 微流控, 药物递送, 联合治疗

Abstract:

Zein shows great potential in anti-cancer drug delivery systems(DDS). However, the zein-based DDS prepared by the traditional method has its shortcomings, such as single function, uneven particle size, poor batch reproducibility and anti-cancer effect. In this work, the quercetin(chemical drug)-TCPP(photosensitizer) was used as the model drug(QT). The co-assembly of the carrier and the model drug was accurately controlled by microfluidic technology. And the HA-zein@QT nanodrug delivery system was precisely constructed to achieve the synergistic anti-tumor. Hyaluronic acid(HA) was used to functionalize α-zein to improve the biocompatibility, stability and cell uptake of the carrier. The microfluidic chip with a high mixing efficiency of 99.54% was screened by computer simulation. The average particle size and PDI of the prepared HA-zein@QT were (50.6±1.7) nm and 0.196, respectively. The results of stability experiments suggested that HA-zein@QT showed high stability after co-incubation with deionized water, PBS and 1640 medium. The results of reactive oxygen species and ·OH detection showed that the 1O2 and ·OH increased after exposure to near-infrared light. HA-zein@QT showed a low hemolysis rate(3.75%) after co-incubation with red blood cells. And a high survival rate(>84.57%) of non-tumor cells was obtained. This evidence indicated that the prepared DDS had high biocompatibility. The cytotoxicity experiment showed that the survival rates of A549, HCT116 and HCT8 cells were 28.2%, 20.2% and 24.6%, respectively. This indicated that HA-zein@QT had a high inhibitory ability to tumor cells. It is expected that the microfluidics precise construction of zein-based DDS will provide a new strategy for achieving high efficiency and minimal side effects in anti-tumor drug delivery.

Key words: Zein, Microfluidic, Drug delivery, Combination therapy

中图分类号: 

TrendMD: